« Back
Home /
Nisoldipine

Nisoldipine

Item no.	S1748-1000
Manufacturer	Selleckchem
CASRN	63675-72-9
Amount	1 g
Quantity options	1 g 10 mM/1 ml 200 mg 50 mg
Category	Oncology Neuroscience Molecular Targets for Neuroscience Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Type	Inhibitors
Specific against	other
Smiles	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BAY K 5552
Similar products	Nisoldipine
Available
Manufacturer - Targets	CAV1
Storage Conditions	2 years -80 in solvent
Molecular Weight	388, 41
Administration	Oral every day
Animal Models	Male Wistar rats with chronic intragastric ethanol exposure
Cell lines	Ventricular myocytes
Clinical Trials	Phase I has been completed in a single-dose fasting bioequivalence study of Nisoldipine extended-release tablets in healthy volunteers.
Concentrations	Dissolved in DMSO, final concentration 10-100 uM
Dosages	10 mg/kg
Formulation	Dissolved in DMSO and diluted in saline
IC50	10 nM [1], 10 nM [1], 10 nM [1], 10 nM [1], 10 nM [1], 10 nM [1]
In vitro	Nisoldipine is a potent blocker of L-type calcium channels. Nisoldipine binds directly to inactive calcium channels stabilizing their inactive conformation Similar to other DHP CCBs. Nisoldipine displays selectivity for arterial smooth muscle cells due to great number of inactive channels and the alpha1 subunit of the channel. [1] Nisoldipine is about 30 times less selective for delayed-rectifier K+ channels than for L-type Ca2+ channels, which inhibits IKr (rapidly activating delayed-rectifier K+ current) with IC50 of 23 uM, and IKs (slowly activating delayed-rectifier K+ current)with IC50 of 40 uM in guinea-pig ventricular myocytes. [2] Nisoldipine also displays antioxidant potency with IC50 of 28.2 uM both before and after the addition of active oxygen. This is tested by means of rat myocardial membrane lipid peroxidation with a nonenzymatic active oxygen-generating system (DHF/FeC13-ADP). [3]
In vivo	Nisoldipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through L-type calcium channels. This results in vasodilation and an overall decrease in blood pressure, based on which Nisoldipine is used to treat mild to moderate essential hypertension, chronic stable angina and Prinzmetal's variant angina. [4] Nisoldipine shows some ability in patients with Timothy syndrome having Cav1.2 missense mutation G406R, with IC50 of 267 nM, which is helpful to treat TS. [5]
Incubation Time	8-10 minutes
Kinase Assay	Binding experiments of, electrophysiology, CHO cells expressing the subunit of the voltage-dependent L-type Ca2+ channel are cultrured in medium without serum in the presence of different concentrations of Nisoldipine. Then Ca2+ channel current elicited from a holding potential of -100 mV or -50 mV is recorded at room temperature with the whole-cell configuration of the patch-clamp method using the List EPC-7 patch-clamp amplifer and pClamp software. The concentration of competitor inhibiting 50% of the specific binding represents IC50.
Method	The myocytes are bathed in normal Tyrode's solution, held at -80 mV, and depolarised after 200-ms prepulses (-40mV) to more positive potentials for 500 ms at 0.1 Hz, tail currents are recorded on repolarisations to -40mV. The myocytes are exposed to 10-100 mM Nisoldipine for 8-10 minutes. Then the whole-cell membrane currents are recorded using an EPC-7 amplifier.
Solubility (25C)	DMSO 78 mg/mL, Water <1 mg/mL, Ethanol 78 mg/mL
Information	Nisoldipine (Sular, BAY K 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM.
Features	Nisoldipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

S1748-1000-datasheet.pdf

S1748-1000-safety-datasheet.pdf